Anna Jovanovich is a Nephrology physician. OpenAlex indexes 85 publications with 1,779 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
931 Highland Blvd Ste 3260
Bozeman, MT 597156907
Telephone
406-414-2410Provider last certified this registry record 9 Apr 2025.
Clinical trials
- Phosphate Lowering in CKD Trial
Sponsor: VA Office of Research and Development
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Horizon Therapeutics plcProgram year20231 payment
- Fresenius USA Marketing, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
64.1%Angiotensin receptor blocker (ARB)12.2%Losartan Potassium85%Valsartan15%Part D<11 patientsACE inhibitor11.5%Lisinopril100%Part D≥20 patients+ 8 more classes in this area
Metabolism & gastrointestinal
20.6%Potassium supplement7.8%Potassium Chloride100%Part D≥19 patientsSGLT2 inhibitor7.4%Jardiance75%Farxiga26%Part D<11 patients+ 2 more classes in this area
Blood & clotting
6.4%Solutions for parenteral nutrition6.4%Calcium Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of bisphosphonates in chronic kidney disease is associated with cardiovascular death
Clinical Nephrology
2024 - Effect of Pravastatin on Kidney Disease Outcomes in Adult Patients with Early-Stage Autosomal Dominant Polycystic Kidney Disease
Journal of the American Society of Nephrology
2024 - Sex Hormones and Vascular Endothelial Function in Men and Women with CKD
Journal of the American Society of Nephrology
2024 - Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics
Contemporary Clinical Trials
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”